Cabozantinib shows significant first-line activity for differentiated thyroid cancer
Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive ...
Feb 13, 2018